Provides prenatal genetic tests for pregnant patients and blood-based cancer tests for cancer patients and their physicians to guide treatment and monitor response.
10-K for FY2025, filed Mar 11, 2026
Prenatal testing is the main source of revenue; insurers, government health programs, or patients are billed when results are delivered to the ordering physician. Clinical-trial work brings milestone and testing-service payments.
10-K for FY2025, filed Mar 11, 2026
10-K for FY2025, filed Mar 11, 2026
FY2025 revenue by product or service ↗$305.1M
10-K for FY2025, filed Mar 11, 2026
$305.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Prenatal
Sold outright
10-K for FY2025, filed Mar 11, 2026 |
91% |
Prenatal, FY2025
$277.1M Sources
|
Sold outright |
|
Oncology
Sold outright
10-K for FY2025, filed Mar 11, 2026 |
8.2% |
Oncology, FY2025
$25M Sources
|
Sold outright |
|
Clinical trial support and other services
|
1.0% |
Clinical trial support and other services, FY2025
$3.1M Sources
|
Patients are the primary customers; physicians and other providers order tests, and insurers, government health programs or patients are billed after results are delivered.
10-K for FY2025, filed Mar 11, 2026
Yes. It kept 2 cents of every revenue dollar as net income in FY2025 and turned 5 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Aug 5, 2026
BillionToOne continues to expect full year 2026 total revenue of $450.0 million to $465.0 million, representing growth of 48% to 52%…View ↗
Competes with Illumina, Verinata, Labcorp, Myriad, Natera, Quest, Fulgent Genetics, Caris Life Sciences, Foundation Medicine, Guardant Health, NeoGenomics Laboratories, Tempus AI, Exact Sciences, Grail, and Haystack
10-K for FY2025, filed Mar 11, 2026In the prenatal market, our main competitors offering NIPTs include Illumina, through its subsidiary Verinata, Laboratory Corporation of…View ↗
Loading...